Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation
Hyperfine (Nasdaq: HYPR) has announced a strategic collaboration with NVIDIA to enhance its AI-powered portable MRI technology. The partnership focuses on advancing the Swoop® system, the first FDA-cleared AI-powered portable magnetic resonance brain imaging system.
The collaboration aims to leverage NVIDIA's AI expertise and accelerated computing to make brain MRI faster, smarter, and more affordable globally. Using NVIDIA's advanced suite of training and inference tools, including NVIDIA DALI and MONAI, the partnership will work on improving image quality, reducing scan times, and enabling faster diagnoses.
This initiative addresses a critical healthcare gap, as 90% of the global population lacks access to timely MRI diagnostics due to conventional MRI systems' high costs and infrastructure requirements. The Swoop® system is designed for point-of-care use in professional healthcare settings by trained clinicians, targeting the over three billion people worldwide affected by brain diseases.
Hyperfine (Nasdaq: HYPR) ha annunciato una collaborazione strategica con NVIDIA per migliorare la sua tecnologia MRI portatile alimentata dall'IA. Il partenariato si concentra sull'avanzamento del system Swoop®, il primo sistema di imaging cerebrale a risonanza magnetica portatile alimentato dall'IA e approvato dalla FDA.
La collaborazione mira a sfruttare l'expertise di NVIDIA nell'IA e nel calcolo accelerato per rendere la risonanza magnetica cerebrale più veloce, intelligente e accessibile a livello globale. Utilizzando l'avanzato pacchetto di strumenti di training e inferenza di NVIDIA, tra cui NVIDIA DALI e MONAI, il partenariato lavorerà per migliorare la qualità delle immagini, ridurre i tempi di scansione e abilitare diagnosi più rapide.
Questa iniziativa affronta un'importante lacuna nella sanità, poiché il 90% della popolazione globale non ha accesso a diagnosi MRI tempestive a causa dei costi elevati e dei requisiti infrastrutturali dei sistemi MRI convenzionali. Il sistema Swoop® è progettato per l'uso sul campo in contesti sanitari professionali da parte di clinici formati, mirando a oltre tre miliardi di persone in tutto il mondo colpite da malattie cerebrali.
Hyperfine (Nasdaq: HYPR) ha anunciado una colaboración estratégica con NVIDIA para mejorar su tecnología de MRI portátil impulsada por IA. La asociación se centra en avanzar en el sistema Swoop®, el primer sistema de imágenes por resonancia magnética cerebral portátil impulsado por IA que ha sido aprobado por la FDA.
La colaboración tiene como objetivo aprovechar la experiencia en IA y la computación acelerada de NVIDIA para hacer que la MRI cerebral sea más rápida, más inteligente y más asequible a nivel global. Utilizando el avanzado conjunto de herramientas de entrenamiento e inferencia de NVIDIA, incluyendo NVIDIA DALI y MONAI, la asociación trabajará en mejorar la calidad de las imágenes, reducir los tiempos de escaneo y permitir diagnósticos más rápidos.
Esta iniciativa aborda una brecha crítica en la atención médica, ya que el 90% de la población mundial no tiene acceso a diagnósticos de MRI oportunos debido a los altos costos y los requisitos de infraestructura de los sistemas de MRI convencionales. El sistema Swoop® está diseñado para su uso en el punto de atención en entornos de atención médica profesional por clínicos capacitados, dirigido a más de tres mil millones de personas en todo el mundo afectadas por enfermedades cerebrales.
Hyperfine (Nasdaq: HYPR)는 NVIDIA와 협력하여 AI 기반의 휴대용 MRI 기술을 향상시키는 전략적 협력을 발표했습니다. 이 파트너십은 FDA 승인을 받은 최초의 AI 기반 휴대용 자기공명 뇌 영상 시스템인 Swoop® 시스템의 발전에 중점을 두고 있습니다.
협력의 목표는 NVIDIA의 AI 전문 지식과 가속 컴퓨팅을 활용하여 뇌 MRI를 전 세계적으로 더 빠르고, 더 스마트하며, 더 저렴하게 만드는 것입니다. NVIDIA DALI 및 MONAI를 포함한 NVIDIA의 고급 교육 및 추론 도구 모음을 사용하여, 이 파트너십은 이미지 품질 개선, 스캔 시간 단축 및 더 빠른 진단을 가능하게 하기 위해 노력할 것입니다.
이 이니셔티브는 전 세계 인구의 90%가 기존 MRI 시스템의 높은 비용과 인프라 요구 사항으로 인해 적시에 MRI 진단을 받을 수 없는 중요한 의료 격차를 해결합니다. Swoop® 시스템은 훈련된 임상의가 전문 의료 환경에서 사용할 수 있도록 설계되었으며, 뇌 질환에 영향을 받는 30억 명 이상의 사람들을 대상으로 하고 있습니다.
Hyperfine (Nasdaq: HYPR) a annoncé une collaboration stratégique avec NVIDIA pour améliorer sa technologie d'IRM portable alimentée par l'IA. Ce partenariat se concentre sur l'avancement du système Swoop®, le premier système d'imagerie cérébrale par résonance magnétique portable alimenté par l'IA et approuvé par la FDA.
La collaboration vise à tirer parti de l'expertise en IA et de l'informatique accélérée de NVIDIA pour rendre l'IRM cérébrale plus rapide, plus intelligente et plus abordable à l'échelle mondiale. En utilisant l'ensemble avancé d'outils de formation et d'inférence de NVIDIA, y compris NVIDIA DALI et MONAI, le partenariat travaillera à améliorer la qualité des images, à réduire les temps de scan et à permettre des diagnostics plus rapides.
Cette initiative répond à une lacune critique dans les soins de santé, car 90 % de la population mondiale n'a pas accès à des diagnostics IRM en temps opportun en raison des coûts élevés et des exigences d'infrastructure des systèmes IRM conventionnels. Le système Swoop® est conçu pour une utilisation sur le terrain dans des environnements de soins de santé professionnels par des cliniciens formés, visant plus de trois milliards de personnes dans le monde touchées par des maladies cérébrales.
Hyperfine (Nasdaq: HYPR) hat eine strategische Zusammenarbeit mit NVIDIA angekündigt, um seine KI-gestützte tragbare MRI-Technologie zu verbessern. Die Partnerschaft konzentriert sich auf die Weiterentwicklung des Swoop®-Systems, des ersten von der FDA zugelassenen KI-gestützten tragbaren magnetresonanztomographischen Gehirn- bildgebungssystems.
Die Zusammenarbeit zielt darauf ab, die KI-Expertise und die beschleunigte Rechenleistung von NVIDIA zu nutzen, um die Gehirn-MRI weltweit schneller, intelligenter und erschwinglicher zu machen. Mithilfe von NVIDIAs fortschrittlichem Set an Trainings- und Inferenzwerkzeugen, einschließlich NVIDIA DALI und MONAI, wird die Partnerschaft daran arbeiten, die Bildqualität zu verbessern, die Scanzeiten zu verkürzen und schnellere Diagnosen zu ermöglichen.
Diese Initiative schließt eine kritische Lücke im Gesundheitswesen, da 90 % der Weltbevölkerung aufgrund der hohen Kosten und Infrastrukturanforderungen herkömmlicher MRI-Systeme keinen Zugang zu zeitgerechten MRI-Diagnosen hat. Das Swoop®-System ist für den Einsatz am Ort der Versorgung in professionellen Gesundheitsumgebungen durch geschulte Kliniker konzipiert und richtet sich an über drei Milliarden Menschen weltweit, die von Gehirnerkrankungen betroffen sind.
- Strategic partnership with major tech company NVIDIA to enhance AI capabilities
- First-mover advantage with FDA-cleared portable MRI technology
- Addresses large untapped market with 90% of global population lacking MRI access
- Potential for improved operational efficiency through reduced scan times
- None.
Insights
Hyperfine's strategic partnership with NVIDIA represents a potentially significant development for this micro-cap company's core technology. The collaboration aims to enhance Hyperfine's Swoop® system - the first FDA-cleared AI-powered portable magnetic resonance brain imaging system - by leveraging NVIDIA's advanced AI capabilities.
The technical collaboration focuses on three key areas: advancing AI-powered image reconstruction, embedding real-time clinical decision support, and improving image quality while reducing scan times. These enhancements directly address core performance metrics that could accelerate clinical adoption of Hyperfine's portable MRI technology.
What makes this partnership particularly notable is the market opportunity: brain diseases affect over 3 billion people worldwide, yet 90% of the global population lacks access to timely MRI diagnostics due to the high cost and infrastructure demands of conventional systems. Hyperfine's technology specifically targets this accessibility gap.
For investors, this NVIDIA collaboration provides technical validation and potential acceleration of Hyperfine's development roadmap. However, the announcement lacks specific details on financial terms, implementation timeline, or quantifiable performance improvements expected. The ultimate value will depend on successful execution and whether technological improvements translate to faster market adoption and revenue growth.
This NVIDIA partnership positions Hyperfine to potentially strengthen its competitive advantage in the point-of-care neuroimaging space. By collaborating with a leader in AI acceleration, Hyperfine addresses a fundamental challenge in portable MRI technology - balancing image quality with accessibility and speed.
The market dynamics here are compelling: conventional MRI systems require significant infrastructure, specialized technicians, and substantial capital investment. Hyperfine's approach of enabling any trained clinician to operate their system at the point of care fundamentally disrupts the traditional neuroimaging workflow and expands the addressable market.
NVIDIA's AI tools like DALI and MONAI should help Hyperfine overcome key technical limitations in portable MRI technology. Better image reconstruction algorithms and real-time clinical decision support could substantially improve diagnostic confidence - a critical factor for physician adoption.
For a company with Hyperfine's market cap (
While financial terms aren't disclosed, this partnership appears strategically aligned with Hyperfine's mission to democratize access to neuroimaging and could enable them to overcome technical hurdles that have traditionally portable MRI adoption.
Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide.
The AI-powered Swoop® portable MR brain imaging system.
Brain diseases affect over three billion people worldwide1, with conditions such as stroke and neurodegenerative disorders responsible for significant mortality, disability, and economic burden. However,
The collaboration between Hyperfine and NVIDIA will focus on advancing AI-powered image reconstruction and embedding real-time clinical decision support into portable MRI workflow. By leveraging the NVIDIA advanced suite of training and inference tools, such as NVIDIA DALI and MONAI, the collaboration seeks to further improve the Swoop® system’s image quality, reduce scan times, and enable faster, more reliable diagnoses.
“Our mission is to make portable brain imaging faster, more intelligent, and increasingly accessible—ultimately improving health outcomes and reducing costs globally,” said Maria Sainz, President and CEO of Hyperfine, Inc. “Partnering with NVIDIA presents an incredible opportunity to advance and accelerate our AI technology. I’m thrilled about the possibilities this collaboration brings for the future.”
For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.
1) World Health Organization. Over 1 in 3 people affected by neurological conditions: The leading cause of illness and disability worldwide. World Health Organization. Published March 14, 2024. Accessed March 13, 2025. https://www.who.int/news/item/14-03-2024-over-1-in-3-people-affected-by-neurological-conditions--the-leading-cause-of-illness-and-disability-worldwide |
2) Ghotbi N, Taki M, Mehrabian F, Alavi N, Khorrami S. Artificial intelligence in stroke imaging: Advances, limitations, and future directions. J Stroke Cerebrovasc Dis. 2023;32(1):106969. doi:10.1016/j.jstrokecerebrovasdis.2022.106969 |
About the Swoop® Portable MR Imaging® System
The Swoop® Portable MR Imaging® system is
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.
The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317452571/en/
Media Contact
Devin Zell
Hyperfine
dzell@hyperfine.io
Investor Contact
Webb Cambell
Gilmartin Group LLC
webb@gilmartinir.com
Source: Hyperfine, Inc.
FAQ
What is the purpose of Hyperfine's collaboration with NVIDIA for the HYPR stock?
How does the Swoop system by Hyperfine (HYPR) differentiate from conventional MRI systems?
What market opportunity is Hyperfine (HYPR) addressing with its portable MRI technology?
What specific NVIDIA technologies will be integrated into Hyperfine's (HYPR) Swoop system?
